A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT ID: NCT06161584
Last Updated: 2025-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
300 participants
OBSERVATIONAL
2023-09-28
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
NCT07214740
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
NCT04770545
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
NCT07215390
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
NCT02503332
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observation
Pegcetacoplan
Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pegcetacoplan
Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient age ≥60 years
* Visual acuity better than 20/200 on Snellen chart
* Clinical diagnosis of GA of the macula secondary to AMD in one or both eyes as determined by the investigator using OCT and/or FAF imaging
* GA lesion meeting the following criteria as determined by the investigator's assessment of Spectralis OCT and/or FAF images at screening:
1. Nonsubfoveal lesion(s)
2. GA lesion visualized in its entirety on the macula-centered OCT image and not contiguous with any areas of peripapillary atrophy
3. Presence of any pattern of hyperautofluorescence in the junctional zone of GA; absence of hyperautofluorescence (ie, pattern = none) exclusionary
* Adequate clarity of ocular media and adequate pupillary dilation and fixation to permit the collection of good quality images as determined by the investigator
* Patient willing and able to give informed consent and to comply with the study procedures and assessments
Exclusion Criteria
* Active, suspected, or history of intraocular inflammation in either eye at screening or on day 1
* Any history of or active choroidal neovascularization associated with AMD or any other cause, including any evidence of retinal pigment epithelial tears or rips in SD OCT imaging
* Presence of an active ocular disease that in the opinion of the investigator compromises or confounds visual function, including but not limited to uveitis and other macular diseases (eg, clinically significant epiretinal membrane, full thickness macular hole, uncontrolled glaucoma/ocular hypertension). Conditions that in the opinion of the investigator are benign, such as peripheral retina dystrophy, are not exclusionary
* Any prior treatment with anti-VEGF agents
* Intraocular surgery (including lens replacement surgery) within 3 months prior to screening
* History of laser therapy in the macular region
* Aphakia or absence of the posterior capsule. Note: Yttrium aluminum garnet laser posterior capsulotomy for posterior capsule opacification done at least 60 days prior to screening is not exclusionary.
* Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period or, in the opinion of the investigator, could compromise visual function during the study period
* Any contraindication to IVT injection
* Current ocular or periocular infection in either eye
* Intravitreal medical device placement
* Participation in any prior or current systemic experimental treatment within 6 weeks or 5 half lives of the active ingredient (whichever is longer) prior to the start of study treatment or in any other investigational treatments specific to GA. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary
* Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up unlikely or would make the patient an unsafe study candidate
* Known hypersensitivity to fluorescein sodium for injection or hypersensitivity to pegcetacoplan or any of the excipients in pegcetacoplan solution
* History or current use of brolucizumab and/or pharmacological treatments that gain approval for the treatment of GA
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Apellis Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
California Retina Consultants (01-026)
Bakersfield, California, United States
Retina-Vitreous Associates Medical Group (01-020)
Beverly Hills, California, United States
Illinois Retina Associates (01-035)
Fullerton, California, United States
Retinal Consultants Medical Group Inc (01-008)
Modesto, California, United States
Retina Consultants San Diego Inc. (01-018)
Poway, California, United States
California Retina Consultants (01-027)
Santa Barbara, California, United States
Bay Area Retina Associates (01-005)
Walnut Creek, California, United States
Colorado Retina Associates, PLLC (01-011)
Lakewood, Colorado, United States
Retina Specialty Institute (01-019)
Pensacola, Florida, United States
South East Retina Center, PC (01-030)
Augusta, Georgia, United States
Georgia Retina (01-032)
Marietta, Georgia, United States
Illinois Retina Associates (01-037)
Oak Park, Illinois, United States
The Retina Care Center (01-023)
Baltimore, Maryland, United States
Cumberland Valley Retina Consultants, P.C. (01-002)
Hagerstown, Maryland, United States
Mid Atlantic Retina Specialist (01-029)
Hagerstown, Maryland, United States
Retina Consultants of Minnesota, PLLC (01-025)
Edina, Minnesota, United States
Mid Atlantic Retina Research (01-014)
Cherry Hill, New Jersey, United States
Mid Atlantic Retina (01-031)
Cherry Hill, New Jersey, United States
OCLI Research Department (01-007)
Oceanside, New York, United States
Long Island Vitreoretinal Consultants (01-013)
Westbury, New York, United States
Western Carolina Retinal Associates, PA (01-009)
Asheville, North Carolina, United States
Retina Associates of Cleveland, Inc. (01-017)
Cleveland, Ohio, United States
Retina Associates of Cleveland, Inc. (01-022)
Cleveland, Ohio, United States
Retina Associates of Cleveland, Inc. (01-016)
Youngstown, Ohio, United States
Mid Atlantic Retina (01-001)
Bethlehem, Pennsylvania, United States
The Retina Care Center (01-034) - Satellite Site
York, Pennsylvania, United States
Black Hills Regional Eye Institute (01-010)
Rapid City, South Dakota, United States
Tennessee Retina (01-033)
Nashville, Tennessee, United States
Integrated Clinical Research (01-024)
Abilene, Texas, United States
Retina Consultants of Texas (01-004)
Bellaire, Texas, United States
Texas Retina Associates (01-028)
Dallas, Texas, United States
Retina Consultants of Texas (01-003)
The Woodlands, Texas, United States
The Retina Group of Washington (01-021)
Fairfax, Virginia, United States
Pacific Northwest Retina (01-036)
Bellevue, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APL2-GA-411
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.